ADMA 16.55 ADMA Biologics, Inc.
| Range: | 3.06-21.13 | Vol Avg: | 5148459 | Last Div: | 0 | Changes: | 0.14 |
| Beta: | 0.62 | Cap: | 4.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Oct 17 2013 | Empoloyees: | 624 | ||
| CUSIP: | 000899104 | CIK: | 0001368514 | ISIN: | US0008991046 | Country: | US |
| CEO: | Mr. Adam S. Grossman | Website: | https://www.admabiologics.com | ||||
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Stock Details
Negative -0.25
ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Biologics Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally reco...
globenewswire.com·Wed Oct 16 2024
Negative -0.20
Investors who lost money on ADMA Biologics, Inc. should contact Levi & Korsinsky about an ongoing investigation - ADMA
NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it...
https://www.accesswire.com/viewarticle.aspx?id=931615&lang=en·Tue Oct 15 2024
Positive 0.31
ADMA LEGAL NOTICE: ADMA Biologics, Inc. is being Investigated for Securities Fraud after Auditor Resignation; Investors with Losses are Urged to Contact BFA Law (Nasdaq:ADMA)
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & ...
https://www.globenewswire.com/news-release/2024/10/15/2963000/0/en/ADMA-LEGAL-NOTICE-ADMA-Biologics-Inc-is-being-Investigated-for-Securities-Fraud-after-Auditor-Resignation-Investors-with-Losses-are-Urged-to-Contact-BFA-Law-Nasdaq-ADMA.html·Tue Oct 15 2024
Positive 0.31
ADMA SHAREHOLDER ALERT: ADMA Biologics, Inc. is Under Investigation for Securities Fraud after Auditor Resignation and 20% Stock Drop; Investors are Urged to Contact BFA Law (Nasdaq:ADMA)
NEW YORK, Oct. 13, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & ...
globenewswire.com·Sun Oct 13 2024
Positive 0.31
ADMA FRAUD ALERT: BFA Law is Investigating ADMA Biologics, Inc. for Securities Fraud after Stock Drops 20%; Investors with Losses are Urged to Contact the Firm (Nasdaq:ADMA)
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & ...
globenewswire.com·Fri Oct 11 2024
Positive 0.58
5 Stocks With Recent Price Strength Amid October Volatility
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price...
zacks.com·Fri Oct 11 2024
Positive 0.63
ADMA Biologics, Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses...
globenewswire.com·Thu Oct 10 2024
Positive 0.31
ADMA STOCK DROP ALERT: ADMA Biologics, Inc. Stock Drops over 20%; BFA Law Initiates Securities Fraud Investigation and Urges Investors with Losses to Contact the Firm (Nasdaq:ADMA)
NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Leading securities law firm Bleichmar Fonti...
accesswire.com·Thu Oct 10 2024
Negative -0.50
Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts
The latest trading day saw Adma Biologics (ADMA) settling at $20.33, representing a -1.91%...
zacks.com·Wed Oct 09 2024
Positive 0.44
The Real Best Stock Of The Year Isn't In The S&P 500 Yet
If you're like most investors — you assume AI giant Nvidia is the best stock of the year. ...
investors.com·Mon Oct 07 2024
Positive 0.40
New Strong Buy Stocks for October 7th
ADMA, VERX, TRGP, EBMT and TALO have been added to the Zacks Rank #1 (Strong Buy) List on ...
zacks.com·Mon Oct 07 2024
Negative -0.10
ADMA Biologics: Riding High On ASCENIV's Success
ADMA Biologics reported $107.2 million in Q2 2024 revenue, a 78% year-over-year increase, ...
seekingalpha.com·Wed Oct 02 2024
Positive 0.40
Biotech Hangs On To Top Spot On This List, And It Even Outshines Nvidia
This biopharma stock has gained around 330% so far this year and is near record highs....
investors.com·Fri Sep 27 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow